ArticleBMC complementary medicine and therapies2025
Endometriosis-like lesions induced by phthalates: new phytotherapic applications to complement traditional cares: a PNRR 2023 project.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundEndometriosis (E) is an oestrogen-dependent, multifactorial, inflammatory disease causing pelvic pain and infertility. Several concerns have been raised about the role of food contaminants, in particular Bis(2-ethylhexyl) phthalate (DEHP), potentially involved in the onset and propagation of E. Conventional therapies- which have considerable side effects - focus on reducing levels of oestrogens and counteracting inflammation. The potential preventive/protective role of plant extracts (PEs) on phthalate (PH) -induced E is studied by a stepwise approach.
methods(i) raw material identification, extraction and phytochemical characterization; (ii) in vitro tests to evaluate pharmacokinetics and organotropism; (iii) in vitro screening on 2 human endometrial cell lines and in vivo toxicokinetic to select the PEs/BCs in comparison with non-steroidal anti-inflammatory drugs; (iv) in vivo juvenile toxicity study to test the PE/BC activity on DEHP induced E-like lesions and (v) ex vivo and in vitro studies on human E primary cells obtained by patients with E to be subjected to scheduled surgical procedures and human non-cancerous cells, to investigate the DEHP and metabolite concentration and PE/BC effects, respectively. DISCUSSION: The project aims to provide data and tools to develop a new strategy based on herbal medicine- especially polyphenolic compounds for their pleiotropic activities - to mitigate the E symptoms and to prevent and/or to protect population - including susceptible sub-groups - from the onset of E. The outcomes of the project will support the Italian National Health System in the development of complementary alternative/preventive strategies for E and to set clinical studies on humans also considering the potential role of environmental contaminants in E pathogenesis. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.